Eurizon Capital SGR S.p.A. Acquires New Stake in Pfizer Inc. $PFE

Key Points

• Eurizon Capital SGR opened a new position in Pfizer during the fourth quarter, buying 1,983,123 shares worth about $49.4 million.
• Pfizer’s latest quarterly results beat expectations, with EPS of $0.75 and revenue of $14.45 billion, both above analyst estimates. The company also guided for FY 2026 EPS of $2.80 to $3.00.
• Pfizer declared a quarterly dividend of $0.43 per share, implying an annualized yield of about 6.6%. The article also notes recent positive pipeline news, including a major oncology collaboration with Innovent Biologics and strong LORBRENA trial data.

Eurizon Capital SGR S.p.A. acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,983,123 shares of the biopharmaceutical company's stock, valued at approximately $49,387,000.

Several other institutional investors have also bought and sold shares of PFE. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Pfizer during the second quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PFE shares. Royal Bank Of Canada restated an "underperform" rating and set a $25.00 target price on shares of Pfizer in a research report on Monday, April 20th. Guggenheim increased their target price on Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. BMO Capital Markets restated an "outperform" rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Daiwa Securities Group downgraded Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. Finally, Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.82.

Pfizer Trading Up 0.2%

Pfizer stock opened at $26.18 on Friday. The stock has a market cap of $149.23 billion, a P/E ratio of 19.99 and a beta of 0.35. Pfizer Inc. has a fifty-two week low of $23.06 and a fifty-two week high of $28.75. The firm's fifty day moving average price is $26.77 and its 200-day moving average price is $26.28. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer's dividend payout ratio is presently 131.30%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.